MX390480B - Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas. - Google Patents
Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.Info
- Publication number
- MX390480B MX390480B MX2019008865A MX2019008865A MX390480B MX 390480 B MX390480 B MX 390480B MX 2019008865 A MX2019008865 A MX 2019008865A MX 2019008865 A MX2019008865 A MX 2019008865A MX 390480 B MX390480 B MX 390480B
- Authority
- MX
- Mexico
- Prior art keywords
- tofogliflozin
- preparations containing
- producing same
- solid preparations
- containing tofogliflozin
- Prior art date
Links
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 title abstract 3
- 229950006667 tofogliflozin Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 239000000654 additive Substances 0.000 abstract 2
- 230000000996 additive effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000007907 direct compression Methods 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013273060 | 2013-12-27 | ||
| PCT/JP2014/084561 WO2015099139A1 (ja) | 2013-12-27 | 2014-12-26 | トホグリフロジンを含有する固形製剤及びその製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019008865A MX2019008865A (es) | 2019-09-13 |
| MX390480B true MX390480B (es) | 2025-03-20 |
Family
ID=53478978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008527A MX370342B (es) | 2013-12-27 | 2014-12-26 | Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas. |
| MX2019008865A MX390480B (es) | 2013-12-27 | 2014-12-26 | Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008527A MX370342B (es) | 2013-12-27 | 2014-12-26 | Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10231930B2 (enExample) |
| EP (2) | EP3087989B1 (enExample) |
| JP (5) | JP6513030B2 (enExample) |
| KR (2) | KR102395687B1 (enExample) |
| CN (2) | CN105828826B (enExample) |
| AU (1) | AU2014370847B2 (enExample) |
| BR (1) | BR112016013164B1 (enExample) |
| CA (1) | CA2934832C (enExample) |
| DK (1) | DK3087989T3 (enExample) |
| ES (1) | ES2704065T3 (enExample) |
| HR (1) | HRP20182199T1 (enExample) |
| HU (1) | HUE041983T2 (enExample) |
| LT (1) | LT3087989T (enExample) |
| MX (2) | MX370342B (enExample) |
| PL (1) | PL3087989T3 (enExample) |
| PT (1) | PT3087989T (enExample) |
| RU (1) | RU2700164C2 (enExample) |
| SI (1) | SI3087989T1 (enExample) |
| TR (1) | TR201821042T4 (enExample) |
| TW (2) | TWI774159B (enExample) |
| WO (1) | WO2015099139A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2674428T3 (pl) | 2006-04-07 | 2017-01-31 | Vertex Pharmaceuticals Incorporated | Modulatory transporterów z kasetą wiążącą ATP |
| US10231930B2 (en) * | 2013-12-27 | 2019-03-19 | Chugai Seiyaku Kabushiki Kaisha | Solid preparations containing tofogliflozin and process of producing the same |
| CN108640958B (zh) * | 2017-05-05 | 2021-03-30 | 镇江圣安医药有限公司 | 异苯并呋喃衍生物、其药物组合物和制剂以及用途 |
| CN107811983A (zh) * | 2017-12-04 | 2018-03-20 | 威海贯标信息科技有限公司 | 一种托格列净组合物 |
| CN107759649A (zh) * | 2017-12-12 | 2018-03-06 | 威海贯标信息科技有限公司 | 一种托格列净新晶型 |
| JP2022146628A (ja) * | 2021-03-22 | 2022-10-05 | 旭化成株式会社 | 錠剤及びその製造方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56145214A (en) | 1980-04-11 | 1981-11-11 | Taiho Yakuhin Kogyo Kk | Ubidecarenone tablet |
| JP2626975B2 (ja) | 1987-03-30 | 1997-07-02 | エーザイ株式会社 | 低融点油性物質含有錠剤 |
| ES2082723B1 (es) | 1994-07-20 | 1996-10-01 | Lilly Sa | Formulacion farmaceutica de fluoxetina en forma dispersable. |
| JPH10287561A (ja) | 1997-04-11 | 1998-10-27 | Taisho Pharmaceut Co Ltd | イブプロフェン配合固形製剤及びその製造方法 |
| JP2000239185A (ja) | 1999-02-16 | 2000-09-05 | Taisho Pharmaceut Co Ltd | 医薬組成物 |
| JP2006528689A (ja) | 2003-05-06 | 2006-12-21 | ムルイェ、ニルマル | エリスロマイシン誘導体の徐放製剤 |
| JP2005104934A (ja) | 2003-10-01 | 2005-04-21 | Eisai Co Ltd | 新規組成物及びその製造方法 |
| JP4997741B2 (ja) | 2004-11-12 | 2012-08-08 | 大正製薬株式会社 | 低融点薬物含有粉粒体及びその製造方法 |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| PE20090185A1 (es) * | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| JP4072195B2 (ja) | 2007-10-18 | 2008-04-09 | キッセイ薬品工業株式会社 | 速放性経口医薬組成物 |
| TW201011043A (en) * | 2008-06-20 | 2010-03-16 | Chugai Pharmaceutical Co Ltd | Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives |
| KR20110126614A (ko) * | 2009-02-13 | 2011-11-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도 |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2012115249A1 (ja) * | 2011-02-25 | 2012-08-30 | 中外製薬株式会社 | スピロケタール誘導体の結晶 |
| MX2013014135A (es) * | 2011-06-03 | 2014-01-23 | Boehringer Ingelheim Int | Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos. |
| PL2981269T3 (pl) * | 2013-04-04 | 2024-02-05 | Boehringer Ingelheim Vetmedica Gmbh | Leczenie zaburzeń metabolicznych u zwierząt koniowatych |
| US10231930B2 (en) * | 2013-12-27 | 2019-03-19 | Chugai Seiyaku Kabushiki Kaisha | Solid preparations containing tofogliflozin and process of producing the same |
-
2014
- 2014-12-26 US US15/108,335 patent/US10231930B2/en active Active
- 2014-12-26 AU AU2014370847A patent/AU2014370847B2/en active Active
- 2014-12-26 CN CN201480070348.6A patent/CN105828826B/zh active Active
- 2014-12-26 HR HRP20182199TT patent/HRP20182199T1/hr unknown
- 2014-12-26 WO PCT/JP2014/084561 patent/WO2015099139A1/ja not_active Ceased
- 2014-12-26 DK DK14874030.1T patent/DK3087989T3/en active
- 2014-12-26 EP EP14874030.1A patent/EP3087989B1/en active Active
- 2014-12-26 KR KR1020167020083A patent/KR102395687B1/ko active Active
- 2014-12-26 SI SI201431027T patent/SI3087989T1/sl unknown
- 2014-12-26 PT PT14874030T patent/PT3087989T/pt unknown
- 2014-12-26 KR KR1020217019961A patent/KR20210082557A/ko not_active Ceased
- 2014-12-26 RU RU2016130602A patent/RU2700164C2/ru active
- 2014-12-26 CA CA2934832A patent/CA2934832C/en active Active
- 2014-12-26 MX MX2016008527A patent/MX370342B/es active IP Right Grant
- 2014-12-26 PL PL14874030T patent/PL3087989T3/pl unknown
- 2014-12-26 CN CN202110319378.8A patent/CN113058038B/zh active Active
- 2014-12-26 MX MX2019008865A patent/MX390480B/es unknown
- 2014-12-26 EP EP18213096.3A patent/EP3482748A1/en not_active Withdrawn
- 2014-12-26 TW TW109144442A patent/TWI774159B/zh active
- 2014-12-26 TR TR2018/21042T patent/TR201821042T4/tr unknown
- 2014-12-26 JP JP2015555053A patent/JP6513030B2/ja active Active
- 2014-12-26 TW TW103145815A patent/TWI715523B/zh active
- 2014-12-26 HU HUE14874030A patent/HUE041983T2/hu unknown
- 2014-12-26 BR BR112016013164-9A patent/BR112016013164B1/pt active IP Right Grant
- 2014-12-26 ES ES14874030T patent/ES2704065T3/es active Active
- 2014-12-26 LT LTEP14874030.1T patent/LT3087989T/lt unknown
-
2019
- 2019-01-29 US US16/260,530 patent/US10398653B2/en active Active
- 2019-02-22 JP JP2019030773A patent/JP6759390B2/ja active Active
-
2020
- 2020-09-02 JP JP2020147286A patent/JP2020203918A/ja active Pending
-
2022
- 2022-06-01 JP JP2022089651A patent/JP2022116267A/ja active Pending
-
2024
- 2024-02-29 JP JP2024030315A patent/JP2024063140A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001369A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. | |
| MX2015013247A (es) | Formulacion de acetato de abiraterona. | |
| MX374480B (es) | Formulaciones de espiro-isoxazolina de accion prolongada. | |
| CO2017002472A2 (es) | Formulación de acetato de abiraterona | |
| CR20160072A (es) | Compuestos y composiciones como inhibidores de la mek | |
| CR20200082A (es) | Virus chikungunya inmunogénico | |
| PH12015501096A1 (en) | Composition for immediate and extended release | |
| MX390480B (es) | Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas. | |
| GT201500247A (es) | Imidazopiridazinas sustituidas | |
| EP3034082A4 (en) | Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients | |
| BR112015025814A2 (pt) | composição farmacêutica para uso inalatório, processo para a preparação de uma composição farmacêutica, composição sólida para uso como um diluente de pós para inalação e kit para a administração de um fármaco como pó para inalação | |
| UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| PH12016502002A1 (en) | Novel bacteriophage and composition comprising same | |
| CO2019011547A2 (es) | Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol | |
| MX2017009289A (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
| MX2016001138A (es) | Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo. | |
| BR112016028316A2 (pt) | composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| BR112016028083A2 (pt) | Composição oral farmacêutica de isotretinoina e seu processo de preparação | |
| MX2016005227A (es) | Polipéptidos de acción prolongada y métodos para su producción y administración. | |
| PE20151789A1 (es) | N-(2-fluoro-2-fenetil)carboxamidas como nematicidas y endoparasiticidas |